Cancer Gene Therapy (Ad-p53)

Trial Demonstrates Positive Safety Profile and Tumor Regression in Several Cancers

Published in Gene Therapy Weekly, June 2nd, 1997

Researchers from the University of Texas M.D. Anderson Cancer Center reported that the first Adenoviral-p53 (Ad-p53) gene therapy study using the tumor suppressor p53 gene was well-tolerated and showed evidence of clinical activity in patients with non-small-cell lung cancer.

Additionally, the treatment appeared to be more active when used in combination with a common chemotherapeutic agent, cisplatin.

Their work was presented at the 33rd Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Denver, Colorado, May 17-20, 1997.

"The results of this Phase I trial are prelimin, but encouraging," said Dr. Jack A....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry